2015, Number 04
<< Back Next >>
MediSan 2015; 19 (04)
Acute leukemias in the elderly from Santiago de Cuba province
Suárez BLC, Marichall FMA, Macías NMM, Hernández GG, González CI
Language: Spanish
References: 19
Page: 484-491
PDF size: 179.05 Kb.
ABSTRACT
A descriptive and retrospective study of 64 patients older than 60 years with acute
leukemia, assisted in the Hematology Service of "Dr. Juan Bruno Zayas Alfonso" Teaching
General Hospital in Santiago de Cuba was carried out during the five year period 2006-
2011, to determine the main clinical and hematological characteristics at the moment of
diagnosis, as well as the global survival of those affected, although the administered
treatments had no healing criterium. The average age of the elderly was 70 years, in an
age range of 60 to 90; while the non lymphoblastic variety represented 98.4%, and all
the patients presented anemia and thrombocytopenia hematological changes, with
increment in the transfusional requirements. Likewise, the blastos presence in the
peripheral blood was demonstrated in 50% and the hyperleucocytosis in 59.4%, while
the main causes of death were related to the cerebral hemorrhage and the progression of
the disease with the multiorganic infiltration, which led to a very short survival of the
members of this series.
REFERENCES
Cruz González P, Carballo Espinosa RR, Valdivia Domínguez A, Massip Nicot J, García Higuera LR. Mortalidad por tumores malignos más frecuentes en el adulto mayor. Rev Cubana Med Gen Integr. 2011; 27(1): 83-90.
Estey EH. How I treat older patients with AML. Blood. 2000; 96(5): 1670-3.
Watt CD, Bagg A. Molecular dignosis of acute myeloid leukemia. Expert Rev Mol Diagn. 2010; 10(8): 993-1012.
Pulte D, Gondos A, Brenner H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica. 2008; 93(4): 594–600.
Löwenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF, et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood. 2010; 115(13): 2586–91.
Colovic M, Colovic N, Radojkovic M, Stanisavljevic D, Kraguljac N, Jankovic G. Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients. Annals of hematology. 2012; 91(9):1363-70.
Sandes AF, da Costa Ribeiro JC, Barroso RS, Silva MR, Chauffaille ML. Improving the outcomes of elderly patients with acute myeloid leukemia in a Brazilian University Hospital. Clinics (Sao Paulo). 2011; 66(8): 1335-9.
Pérez Bazán LM. Valoración geriátrica como predictor de mortalidad en ancianos con insuficiencia cardíaca descompensada. Bachelor [tesis]. Barcelona: Universidad Autónoma de Barcelona; 2011. p. 48 [citado 12 May 2014].
De Luca D, Vaglio Giors G, Torre AC, Enz P, Rodríguez Chiappetta MF, Galimberti RL. Leucemia cutis. Dermatología Argentina. 2011; 17(2): 123-127.
Schiller GJ, O'Brien SM, Pigneux A, Deangelo DJ, Vey N, Kell J, et al. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J Clin Oncol. 2010; 28(5): 815-21.
Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. 2010; 28(4): 549- 55.
Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. British journal of haematology. 2011; 152(5): 524-42.
Peyrade F, Gastaud L, Ré D, Pacquelet-Cheli S, Thyss A. Treatment decisions for elderly patients with haematological malignancies: a dilemma. The lancet oncology. 2012; 13(8):344-52.
Ofran Y, Rowe JM. Induction and postremission strategies in acute myeloid leukemia: what is new? Current Opin Hematol. 2011; 18(2): 83-8.
Yee KW, Keating A. Older patients with acute myeloid leukemia. Expert review of hematology. 2010; 3(6):755-74.
Extermann M, Wedding U. Comorbidity and geriatric assessment for older patients with hematologic malignancies: A review of the evidence. Journal of Geriatric Oncology. 2012; 3(1):49-57.
Payandeh M, Aeinfar M. Treating the elderly patient with acute myelogenous leukemia. Journal of Hematological Malignancies. 2012; 2(4): 22.
Lagadinou DE, Zoumbos CN, Spyridonidis A. Challenges in Treating Older Patients with Acute Myeloid Leukemia. Journal of Oncology. 2010; (2010): 11.
Larson RA. Treatment of acute myeloid leukemia in older adults. Up to Date. 2012; 18.